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Abstract
BACKGROUND—Primary biliary cirrhosis is a chronic granulomatous cholangitis,
characteristically associated with antimitochondrial antibodies. Twin and family aggregation data
suggest that there is a significant genetic predisposition to primary biliary cirrhosis, but the
susceptibility loci are unknown.
METHODS—To identify genetic loci conferring a risk for primary biliary cirrhosis, we carried
out a genomewide association analysis in which DNA samples from 2072 Canadian and U.S.
subjects (536 patients with primary biliary cirrhosis and 1536 controls) were genotyped for more
than 300,000 single-nucleotide polymorphisms (SNPs). Sixteen of the SNPs most strongly
associated with primary biliary cirrhosis were genotyped in two independent replication sets. We
carried out fine-mapping studies across three loci associated with primary biliary cirrhosis.
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RESULTS—We found significant associations between primary biliary cirrhosis and 13 loci
across the HLA class II region; the HLA-DQB1 locus (encoding the major histocompatibility
complex class II, DQ β chain 1) had the strongest association (P = 1.78×10−19; odds ratio for
patients vs. controls, 1.75). Primary biliary cirrhosis was also significantly and reproducibly
associated with two SNPs at the IL12A locus (encoding interleukin-12α), rs6441286 (P =
2.42×10−14; odds ratio, 1.54) and rs574808 (P = 1.88×10−13; odds ratio, 1.54), and one SNP at the
IL12RB2 locus (encoding interleukin-12 receptor β2), rs3790567 (P = 2.76×10−11; odds ratio,
1.51). Fine-mapping analysis showed that a five-allele haplotype in the 3′ flank of IL12A was
significantly associated with primary biliary cirrhosis (P = 1.15×10−34). We found a modest
genomewide association (P<5.0×10−5) with the risk of disease for SNPs at the STAT4 locus
(encoding signal transducer and activator of transcription 4) and the CTLA4 locus (encoding
cytotoxic T-lymphocyte–associated protein 4) and 10 other loci.
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CONCLUSIONS—Our data show significant associations between primary biliary cirrhosis and
common genetic variants at the HLA class II, IL12A, and IL12RB2 loci and suggest that the
interleukin-12 immunoregulatory signaling axis is relevant to the pathophysiology of primary
biliary cirrhosis. (ClinicalTrials.gov number, NCT00242125.)
Primary biliary cirrhosis is the most common autoimmune liver disease, affecting up to 1 in
1000 women over 40 years of age.1 Treatment for this chronic cholestatic condition remains
empirical.2 The granulomatous destruction of interlobular bile ducts that characterizes
primary biliary cirrhosis is almost always associated with antimitochondrial antibodies
specific for the E2 subunit of the pyruvate dehydrogenase complex.3 The hepatic
accumulation of autoreactive T lymphocytes in patients with primary biliary cirrhosis, as
well as data from animal models of autoimmune cholangitis, implicate T lymphocytes —
CD4+ T helper lymphocytes in particular — in the pathogenesis of primary biliary cirrhosis.
4–6
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A genetic predisposition for primary biliary cirrhosis has been revealed by analysis of both
aggregation data from families and concordance data from twins. The rate of concordance
among monozygotic twins is 60%,7 with the sibling relative risk estimated as 10.5.8 The
coexistence of other autoimmune diseases in patients and the increased prevalence of such
diseases in their families is also consistent with a genetic influence.9,10 Among the genes
studied as susceptibility candidates, only HLA has consistently been associated with primary
biliary cirrhosis. HLA-DRB1*0801 confers an increased risk of primary biliary cirrhosis in
whites, with an odds ratio of 2.4 to 3.3. In addition, the derived population attributable
fraction for HLA-DRB1*08 ranges from 2.8 to 8.8%11,12 (for the derivation, see the
Supplementary Appendix, available with the full text of this article at NEJM.org). Primary
biliary cirrhosis has also been associated — in some, but not all, studies — with variants in
CTLA4 (the gene encoding cytotoxic T-lymphocyte-associated protein 4).13–15 To explore
the genetic basis of primary biliary cirrhosis, we conducted genomewide association
screening of subjects from North America.

METHODS
PATIENTS AND CONTROLS
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We used a two-stage design to analyze data from 2072 white subjects (536 patients and 1536
controls) from North America (Fig. 1). Stage 1 consisted of a genomewide association
survey of patients with primary biliary cirrhosis and controls from Canada, with additional
historical controls from the United States. We carried out replication analyses (stage 2)
involving patients and controls from the United States (stage 2a) and additional patients and
controls from Canada (stage 2b), as well as fine-mapping studies of all Canadian subjects
from the genomewide association screening (stage 1) and replication analysis (stage 2b). We
obtained written informed consent from all subjects, and the study was approved by a local
institutional ethics committee at each center.
All patients fulfilled the criteria of the American Association for the Study of Liver Diseases
for primary biliary cirrhosis,16 and all patients and controls were whites of European origin
(as determined by self-report and, for patients included in stage 1, confirmed by genotyping;
see the Supplementary Appendix). Data from a total of 536 patients with primary biliary
cirrhosis and 1536 healthy controls (399 healthy volunteers in Toronto who had no history
of autoimmune disease, and an additional 1137 historical controls from an M.D. Anderson
lung cancer study17) were included in the stage 1 genomewide association analysis. The
stage 2a replication analysis included data from 410 patients with primary biliary cirrhosis
and 310 controls from the Mayo Clinic Primary Biliary Cirrhosis Registry,14 and stage 2b
included data from additional subjects in Canada (116 patients and 896 controls). The
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genomic data from the Canadian patients and controls in stage 1, which were subject to
quality-control standards, and stage 2b (the additional 116 patients and 896 controls in
Canada) were included in the fine-mapping analyses. Data from all patients and controls (in
stages 1, 2a, and 2b) were included in the combined analysis.
GENOTYPING AND QUALITY CONTROL
DNA purification and genotyping methods are described in the Supplementary Appendix. In
stage 1, samples from the patients and the Canadian controls were genotyped for 373,400
single-nucleotide polymorphisms (SNPs) with the use of the Illumina HumanHap370
BeadChip. Samples from the M.D. Anderson historical controls were genotyped on the
Illumina HumanHap300 BeadChip. Genotyping data were subjected to quality control
before the data analysis (see the Supplementary Appendix). Genotypes were called if they
exceeded minimum quality-control standards. Individual samples with genotype call rates of
less than 95% and SNPs with call rates of less than 95%, minor-allele frequencies of less
than 1%, or deviation from the Hardy–Weinberg equilibrium at P<0.0001 were removed.
Replication and fine-mapping were performed with the use of the Sequenom MassArray
iPLEX genotyping platform.
STATISTICAL ANALYSIS
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For the genomewide association analysis, pairwise identity-by-state analysis was performed
with PLINK software (version 1.05)18 (http://pngu.mgh. harvard.edu/purcell/plink/) to
identify subjects with excess identity-by-descent sharing (PI_HAT >0.25), a measure of the
degree of genetic relationship between subjects. One subject from each of the 15 pairs
exceeding this threshold was removed from the association analysis; the subject in each pair
with the higher average SNP call rate was retained. Hierarchical cluster analysis was
performed with the use of PLINK to identify subjects with similar genotypes over the entire
genome; the 39 samples that were more than 4 SD from a nearest neighbor were removed
from the analysis. Subsequent association analyses were conducted with the use of a
conditional analysis adjusting for stratifications among groups of subjects identified by
hierarchical clustering. To control alternatively for the potential confounding influences of
population stratification, association analysis was also performed on the basis of a principalcomponents analysis implemented in the EIGENSTRAT method19 with default parameters,
in which we adjusted for the 10 eigenvectors having the highest eigenvalues. The lambda
values showed minimal inflation (1.085 before and 1.056 after adjustment for eigenvectors);
with the use of PLINK, the lambda values were 1.14 without adjustment for clusters and
1.09 with adjustment for clusters.
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Allele and genotype associations were assessed by means of PLINK software, and linkage
disequilibrium between pairs of SNPs and haplotypes was determined with the use of
Haploview software, version 4.1 (www.broad.mit.edu/mpg/haploview). Haplotype block
structure was defined according to the criteria established by Gabriel et al.20 and the
pairwise estimates of standardized Lewontin's disequilibrium coefficient (D′), whereas the
linkage disequilibrium among pairs of SNPs was characterized according to the square of
the correlation coefficient (r2).
Combined analyses were carried out with Cochran–Mantel–Haenszel tests and SAS
software, with adjustment for potential confounding of the case or control frequency with
genotype frequency among groups of subjects according to the stage of analysis or center.
Supplementary analyses are described in the Supplementary Appendix.
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RESULTS
GENOMEWIDE ASSOCIATION ANALYSIS (STAGE 1)
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The most significant results of the stage 1 genomewide association survey are shown in
Table 1 and Figures 2 and 3. (The full set is available from the database of Genotypes and
Phenotypes [dbGaP];
www.ncbi.nlm.nih.gov/sites/entrez?db=gap, accession number phs000183.v1.p1). The stage
1 results are based on the analysis of the 305,724 SNPs that passed quality-control standards
and the 505 patients with primary biliary cirrhosis and 1507 controls who were retained after
the pairwise identity-by-state analysis and correction for population stratification.
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Thirteen SNPs across the HLA region on chromosome 6p21.3 and three SNPs from two
distinct non-HLA regions at the IL12A locus, which encodes interleukin-12α (3q25.33–q26),
and the IL12RB2 locus, which encodes interleukin-12 receptor β2 (1p31.2), met a
significance threshold for genomewide association of P<5.0×10−7 (calculated with the
EIGENSTRAT method). The most significantly associated markers according to the
EIGENSTRAT method — rs2856683, rs9275312, rs9275390, and rs7775228 — map to the
region between the HLA-DQB1 gene, which encodes major histocompatibility complex
(MHC) class II, DQ β chain 1, and the HLA-DQA2 gene, which encodes MHC class II, DQ
α chain 2. The P values from the PLINK analysis for these associations were between
1.70×10−10 and 8.58×10−17, with odds ratios for patients as compared with controls that
ranged from 1.81 to 2.01. Highly significant association signals (according to the PLINK
analysis) were also shown for nine other SNPs mapping in or near genes within the HLA
region: C6orf10, which encodes chromosome 6 open reading frame 10 (P = 5.62×10−10);
HLA-DPB1, which encodes MHC class II, DP β chain 1 (P = 8.28×10−9); BTNL2, which
encodes butyrophilin-like 2 (P = 1.27×10−9); and HLA-DRA, which encodes MHC class II,
DR α chain (P = 6.83×10−7). The C6orf10 locus had the strongest association with the risk
of primary biliary cirrhosis (odds ratio, 3.24). Haplotype analysis, however, revealed that 4
of the 13 SNPs (rs2395148, rs3135363, rs2856683, and rs9357152 [in the C6orf10, BTNL2,
HLA-DQB1 and HLA-DQB1 genes, respectively]) accounted for all of the HLA-associated
risk for primary biliary cirrhosis (Table 1 in the Supplementary Appendix). Similar levels of
association were found in a separate analysis of the genomewide data from Canadian
controls only (Table 2 in the Supplementary Appendix).
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Among the non-HLA loci, the strongest signals of association with primary biliary cirrhosis
were found for two SNPs in the IL12A locus, rs6441286 (P = 3.25×10−8; odds ratio for
patients vs. controls, 1.51) and rs574808 (P = 5.34×10−7; odds ratio, 1.47), and one SNP in
the IL12RB2 locus, rs3790567 (P = 8.60×10−8; odds ratio, 1.54). A significant association
with disease was also seen with a second IL12RB2-region SNP, rs3790565 (P = 1.41×10−6).
Twelve other non-HLA loci with association signals at significance levels of P<5.0×10−5
were identified. These included STAT4, which encodes signal transducer and activator of
transcription 4 (rs16833239, P = 2.60×10−5, a locus associated with risks of several other
autoimmune diseases and a downstream biologic mediator of interleukin-12 signaling22;
CTLA4 (rs6748358, P = 1.41×10−5), a locus previously associated with a risk of primary
biliary cirrhosis14,15; and the IRF5–TNPO3 locus (encoding interferon regulatory factor 5
and transportin 3, respectively) (rs10488631) (P = 2.14×10−5which is associated with risk
for systemic lupus erythematosus23 and inflammatory bowel disease.24 These 12 loci were
more modestly associated with primary biliary cirrhosis than were the IL12A and IL12RB2
loci, but the associations with the disease risk were similar, with odds ratios for patients as
compared with controls ranging from 1.38 to 2.13.
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INDEPENDENT REPLICATION (STAGE 2) AND COMBINED ANALYSIS
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We tested for an association between disease and 16 of the most strongly associated SNPs
from the stage 1 analysis, using two independently collected sets of case−control samples
from subjects in the United States (stage 2a analysis) and Canada (stage 2b analysis). We
found replication of the association (P<0.05 from the PLINK analysis in each replication
cohort and P<0.05 with the Bonferroni correction in the joint replication analysis of both
cohorts) with the rs2856683, rs2395148, and rs9277535 SNPs at three distinct sites within
the HLA region as well as the rs6441286–rs574808 and rs3790567 SNPs at the IL12A and
IL12RB2 loci, respectively.
A combined analysis of the genomewide association and replication data sets (from stages 1
and 2) also provided strong evidence (by means of a Cochran–Mantel–Haenszel test) of an
association between primary biliary cirrhosis and the loci HLA-DQB1 (P = 1.78×10−19; odds
ratio for patients vs. controls, 1.75), C6orf10 (P = 3.62×10−14;odds ratio, 2.87), HLA-DPB1
(P = 3.92×10−11; odds ratio, 1.50), BTNL2 (P = 1.11×10−9; odds ratio, 1.42), IL12A (P =
2.42×10−14; odds ratio, 1.54), and IL12RB2 (P = 2.76×10−11; odds ratio, 1.51). We found no
significant effect of antimitochondrial-antibody status on these associations (Table 3 in the
Supplementary Appendix). In addition, we found an increasing risk in association with
increasing numbers of copies of risk alleles for the IL12A and IL12RB2 loci (Tables 4 and 5
in the Supplementary Appendix).
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FINE-MAPPING AND HAPLOTYPE ANALYSES
To refine and further validate the two major non-HLA loci associated with primary biliary
cirrhosis (IL12A and IL12RB2), we genotyped tag SNPs across these loci in samples from all
Canadian patients and controls (Table 2, and Table 6 in the Supplementary Appendix). To
fine-map the IL12A locus, we genotyped 25 SNPs spanning 80 kb and encompassing the
IL12A gene and the regions upstream (5′ end, 38 kb) and downstream (3′ end, 32 kb). We
observed significant associations for multiple SNPs, with the strongest signal generated by
rs4679868, downstream of IL12A (P = 1.58×10−9; odds ratio for patients vs. controls, 1.55).
This variant was not genotyped in stage 1. Through haplotype analyses (Table 7 in the
Supplementary Appendix), we identified a five-allele haplotype, downstream of IL12A,
comprising the rs4679867, rs4679868, rs6441286, rs574808, and rs589545 SNPs (TAGTG),
as a major risk haplotype for primary biliary cirrhosis (P = 4.82×10−29). A combined
analysis of the Canadian and U.S. samples revealed the presence of this haplotype in 49.1%
of all patients (vs. 32.0% of controls) and confirmed the significant association with disease
(P = 1.15×10−34; odds ratio, 2.01).
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To fine-map the IL12RB2 locus, we genotyped 39 tag SNPs spanning 176.1 kb across the
region encompassing IL23R (the gene encoding the interleukin-23 receptor) and IL12RB2.
Included in these tag SNPs were IL23R variants previously shown to be associated with
Crohn's disease and psoriasis.25,26 SNPs in the intronic regions and regions downstream of
IL12RB2 showed the strongest associations with primary biliary cirrhosis; rs6679356
showed the most significant association (P = 7.02×10−8). Moreover, we observed a
significant association between primary biliary cirrhosis and a three-SNP haplotype (GTC)
downstream of IL12RB2 (present in 35.6% of patients and 25.3% of controls; P =
3.07×10−11; odds ratio for patients vs. controls, 1.53) (Table 8 in the Supplementary
Appendix). No significant associations were seen with IL23R SNPs.
Although the association between primary biliary cirrhosis and the rs16833239 SNP in
STAT4 was not replicated, in the combined analysis the association was significant (P =
4.67×10−5; odds ratio for patients vs. controls, 1.65), a finding that may be particularly
relevant to the associations with markers implicating IL12A and IL12RB2. We therefore
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carried out additional genotyping of SNPs across the 94.6-kb STAT4 locus, finding modest
associations between disease and several intronic SNPs. A SNP in intron 3, rs3024921,
showed a significant association (P = 5.76×10−8) in the combined data set (Tables 6 and 9 in
the Supplementary Appendix).
Finally, we performed stepwise selection and conditional analysis of the SNPs from the finemapping analysis across the IL12A, IL12RB2, and STAT4 loci (Table 10 in the
Supplementary Appendix). For each region, we found that multiple alleles underlie the
observed associations.

DISCUSSION
We have identified the HLA, IL12A, and IL12RB2 loci as susceptibility loci for primary
biliary cirrhosis. Our study provides compelling evidence that all three loci are involved in
primary biliary cirrhosis: the successful replication in independent cohorts of the most
strongly associated SNP at each of these loci, the high significance levels in the combined
analysis, and the identification (through ancillary genotyping) of several other SNPs across
the IL12A and IL12RB2 loci that are associated with primary biliary cirrhosis.
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Associations between primary biliary cirrhosis and MHC class II alleles have been
reported12 but have been only inconsistently replicated in other studies. Our data provide
conclusive evidence that this region is involved in primary biliary cirrhosis, with
associations shown between disease and variants in the four HLA class II genes (DQB1,
DPB1, DRB1, and DRA) and the C6orf10 and BTNL2 genes also at this locus. Among these
genes, DQB1, DPB1, and DRB1 have previously been implicated in primary biliary
cirrhosis,27 and the association of a BTNL2 truncating mutation identified initially in
patients with sarcoidosis28 (another granulomatous disease) has also been seen in patients
with other autoimmune diseases. This association may reflect linkage disequilibrium of the
BTNL2 mutation with HLA-DQB1–HLA-DRB1 haplotypes that confer a predisposition to
disease.29,30 Although strong linkage disequilibrium across this region obscures the identity
of the causal alleles under-pinning the associations with primary biliary cirrhosis, haplotype
analyses (Table 1 in the Supplementary Appendix) suggest that most of the risk of primary
biliary cirrhosis derives from two common haplotypes, AACA (P = 1.09×10−10) and CACA
(P = 7.29×10−10), across the C6orf10, BTNL2, and HLA-DQB1 genes. By validating the
MHC class II region as a major contributor to the risk of primary biliary cirrhosis, our data
support further dissection of this region.
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HLA contributions to the risk of primary biliary cirrhosis are proportionately less significant
than the contributions to risks of other autoimmune diseases.31 The association of the HLADQB1 locus with the risk of primary biliary cirrhosis (odds ratio, 1.75) is similar to the
associations of IL12A (odds ratio, 1.54) and IL12RB2 (odds ratio, 1.51). In addition, the
population attributable fraction for the IL12A rs6441286 GT and GG risk genotypes (21.5%)
is slightly higher than that for HLA-DQB1 rs2856683 CC and CA risk genotypes (21.2%)
(Table 11 in the Supplementary Appendix). The IL12RB2 locus also provides a high
population attributable fraction, 18.4%. These estimates suggest substantive contributions of
all three loci to the risk of primary biliary cirrhosis.
Our data suggest important contributions of the IL12A and IL12RB2 loci to susceptibility to
primary biliary cirrhosis. This possibility is consistent with the major immunoregulatory
roles of the protein products, interleukin-12 p35 and interleukin-12 receptor β2, which
associate with the interleukin-12 p40 and interleukin-12 receptor β1 chains, respectively, to
generate interleukin-12 and its receptor. The binding of interleukin-12 to its receptor is
thought to modulate autoimmune responses by evoking interferon-γ production, which may
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in turn inhibit interleukin-23–driven induction of interleukin-17–producing helper T
lymphocytes.32,33 The relevance of this pathway to primary biliary cirrhosis is suggested by
our finding of associations between primary biliary cirrhosis and several SNPs across the
STAT4 gene, which encodes an effector that is integral to interleukin-12 signaling. The SNP
rs7574865 in STAT4 intron 3 is known to be associated with risks of rheumatoid arthritis,
systemic lupus erythematosus,22 and type 1 diabetes34; our findings suggest that it is
associated with primary biliary cirrhosis as well (P = 1.21×10−3; odds ratio, 1.31) (Table 6
in the Supplementary Appendix), although the strongest signals of association at this locus
came from intronic SNPs outside the linkage-disequilibrium block tagged by rs7574865.
Similarly, another SNP associated with primary biliary cirrhosis, rs178105416 in the IL12A
gene, has previously been shown to be associated with the risk of celiac disease,35 whereas
SNPs in the genes encoding interleukin-12β and the interleukin-23 receptor (key
components of the signaling pathway of interleukin-12 and its receptor and the related
interleukin-23 immunomodulatory axis) are associated with risks for psoriasis and
inflammatory bowel disease, although not primary biliary cirrhosis.25,26,36

NIH-PA Author Manuscript

Our genomewide association study had a statistical power of 82% to detect associations with
an odds ratio of 1.5 for patients as compared with controls (see the Supplementary
Appendix) and thus provides strong evidence for associations of primary biliary cirrhosis
with HLA, IL12A, and IL12RB2 variants. However, the lower statistical power of the study
to detect associations with more modest effects, even in the combined analysis (e.g.,
estimated power of 60% to detect associations with an odds ratio of 1.4) may have impeded
the discovery of some risk alleles for primary biliary cirrhosis. Analyses of data from larger
and prospectively followed groups of subjects will be required to identify other non-HLA
loci influencing risk and to elucidate the relevance of the loci associated with primary biliary
cirrhosis to clinically important subphenotypes such as disease progression. Population
stratification appeared to have a minimal effect in our analysis, given the minimal inflation
of the genomewide chi-square statistics and the similar levels of association in the analysis
that was restricted to Canadian subjects.
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The causal alleles at the identified risk loci remain unknown. The strongest associations at
the IL12A and IL12RB2 loci are with SNPs in the downstream and intronic regions,
suggesting that these variants may influence IL12A–IL12RB2 expression. Although it
requires further investigation, this possibility is consistent with the development of
autoimmune and lymphoproliferative disease in IL12RB2 knockout mice37 and a recent
report describing the development of biliary cirrhosis in a child with interleukin-12
deficiency.38 These observations, as well as the cumulative data linking inherited
deficiencies of interleukin-12, interleukin-12 receptor, and interferon-γ to increased
susceptibility to and severity of mycobacterial and other infectious diseases,39 raise the
intriguing possibility that IL12A and IL12RB2 variants associated with primary biliary
cirrhosis engender both an impaired response to infection and a potentiated risk of
autoimmunity, the former possibly driving the latter.
Precise characterization of the nature and functional sequelae of the HLA and IL12A–
IL12RB2 variants that confer a risk of primary biliary cirrhosis remains to be achieved. The
association of primary biliary cirrhosis with variants at these loci confirms the critical role of
immunogenetic factors in the genesis of this disease. These data point to the possibility that
modulation of signaling by interleukin-12 and its receptor may be beneficial in the treatment
of patients with primary biliary cirrhosis.
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Figure 1. Quality Control and Study Design

Panel A shows the outcomes of genotyping quality control for single-nucleotide
polymorphisms (SNPs) and genomic DNA from individual subjects. The requirements for
SNPs to meet quality-control standards were call rates of greater than 95%, P>0.0001 for the
test for Hardy–Weinberg equilibrium, and P>0.01 for the test for minor allele frequency.
Panel B shows the stages of analysis in the study: from stage 1, the genomewide association
screening, through stage 2, the replication analysis, to fine-mapping and haplotype analyses.
IL12A denotes the gene encoding interleukin-12α, IL12RB2 the gene encoding
interleukin-12 receptor β2, IL23R the gene encoding interleukin-23 receptor, and STAT4 the
gene encoding signal transducer and activator of transcription 4.
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Figure 2. Results of the Genomewide Association Analysis
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The y axis represents the level of significance (from the EIGENSTRAT method) for each
single-nucleotide polymorphism on each chromosome along the x axis. The dotted line
indicates the threshold for genomewide association significance.21 The P values were
adjusted in EIGENSTRAT for the 10 eigenvectors having the highest eigenvalues. HLADQB1 denotes the gene encoding major histocompatibility complex class II DQ β chain 1,
IL12A the gene encoding interleukin-12α, IL12RB2 the gene encoding interleukin-12
receptor β2, and STAT4 the gene encoding signal transducer and activator of transcription 4.
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Figure 3. Results of Association Analyses and Linkage-Disequilibrium Blocks for the IL12A and
IL12RB2 Loci

Data are shown for the IL12A (encoding interleukin-12α) locus (Panel A) and the IL12RB2
(encoding interleukin-12 receptor β2) locus (Panel B). The results of chi-square analyses are
presented in the top plots. Underneath the plots, the organization of the target genes and
surrounding loci in humans is shown (not to exact scale). At the bottom, the haplotype block
structure is depicted for 25 genotyped SNPs in the IL12A locus (Panel A) and 30 genotyped
SNPs in the IL12RB2 locus (Panel B). The block structure is based on criteria established by
Gabriel et al.,20 with the use of pairwise estimates of standardized Lewontin's disequilibrium
coefficient (D′), whereas the linkage disequilibrium among pairs of SNPs was characterized
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on the basis of the square of the correlation coefficient (r2). Regions with high r2 values are
dark gray, and regions with lower r2 values are lighter gray (i.e., the shade lightens with
decreasing r2 values).
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0.93

Patients (N = 621)

0.25

0.25

0.13

0.19

0.18

0.18

0.25

0.20

0.59

0.59

0.39

0.39

0.60

0.37

0.58

0.48

0.59

0.42

0.42

0.88

Controls (N = 1279)

1.55 (1.34–1.78)
1.52 (1.32–1.76)
1.49 (1.29–1.73)
1.49 (1.28–1.72)

1.58×10 −9
4.83×10−9
1.15×10−7
1.34×10−7

1.66 (1.37–2.03)
1.52 (1.30–1.77)
1.52 (1.30–1.77)

8.32×10−8
9.87×10−8

1.57 (1.33–1.86)
1.88×10−7

7.02×10

−8

1.49 (1.26–1.76)

1.46 (1.26–1.70)

4.52×10−7

1.50 (1.27–1.79)

1.50 (1.30–1.73)

2.11×10−8

1.93×10−6

1.41 (1.22–1.63)

4.08×10−6

1.52 (1.30–1.77)

1.37 (1.19–1.58)

1.09×10−5

2.44×10−6

1.36 (1.17–1.58)

4.47×10−5

1.53 (1.30–1.79)

1.37 (1.19–1.58)

1.12×10−5

1.22×10−7

1.39 (1.21–1.60)

4.34×10−6

2.76×10−7

1.78 (1.38–2.31)

Odds Ratio (95% Cl)

9.77×10−6

P Value

controls (from the stage 1 and stage 2b analyses). The risk allele for each SNP is underlined. SNPs with significant associations (P<5.0×10−5) with primary biliary cirrhosis are shown. The complete data set
is provided in Table 8 in the Supplementary Appendix. P values and odds ratios are for the comparison of allele frequency between patients and controls, as calculated with the PLINK method. The most
significant association for each of the two loci is shown in bold.

Single-nucleotide polymorphisms (SNPs) across the IL12A locus (encoding interleukin-12α) and the IL12RB2 locus (encoding interleukin-12 receptor β2) were investigated in the Canadian patients and

*

3′-Flanking region

rs6441284

IL12RB2 (chromosome 1p31.2)

3′-Flanking region

Intron 2

rs583911

rs668998

5′-Flanking region

Chromosomal Position

rs17810546

IL12A (chromosome 3q25.33–q26)

SNP

Risk-Allele Frequency
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